Correction to: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial (PLOS Pathogens, (2016), 12, 1, (e1005381), 10.1371/journal.ppat.1005381);Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

PLoS Pathogens

Volumn 12, Issue 1, 2016, Pages

  Serrano Villar, Sergio ^a   Sainz, Talia ^b   Ma, Zhong Min ^c   Utay, Netanya S ^d   Wook Chun, Tae ^e   Mann, Surinder ^f   Kashuba, Angela D ^g   Siewe, Basile ^h   Albanese, Anthony ⁱ   Troia Cancio, Paolo ^f   Sinclair, Elizabeth ^j   Somasunderam, Anoma ^d   Yotter, Tammy ^f   Deeks, Steven G ^j   Landay, Alan ^h   Pollard, Richard B ^f   Miller, Christopher J ^c,f   Moreno, Santiago ^a   Asmuth, David M ^f  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h RUSH UNIVERSITY   (United States)

ⁱ VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; INTEGRASE INHIBITOR; INTERLEUKIN 6; LIPOTEICHOIC ACID; MARAVIROC; RALTEGRAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; DRUG COMBINATION; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CELL COUNTING; CELL DENSITY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DUODENUM BIOPSY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; MASS SPECTROMETRY; MUCOSAL IMMUNITY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM BIOPSY; DRUG COMBINATION; DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CCR5 RECEPTOR ANTAGONISTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANES; DRUG COMBINATIONS; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; IMMUNITY, MUCOSAL; LYMPHOCYTE ACTIVATION; MALE; PILOT PROJECTS; RALTEGRAVIR POTASSIUM; T-LYMPHOCYTE SUBSETS; TRIAZOLES;

EID: 84956774346     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006368     Document Type: Erratum

References (66)

1. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203: 780–90. doi: 10.1093/infdis/jiq118 21252259
2. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. J Infect Dis. 2014;210: 1228–38. doi: 10.1093/infdis/jiu238 24755434
3. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non-AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. J Infect Dis. 2014;210: 1248–59. doi: 10.1093/infdis/jiu254 24795473
4. Deeks SG, Tracy R, Douek DC, Systemic Effects of Inflammation on Health during Chronic HIV Infection. Immunity. Elsevier Inc.; 2013;39: 633–45. doi: 10.1016/j.immuni.2013.10.001 24138880
5. Gordon SN, Cervasi B, Odorizzi P, Silverman R, Aberra F, Ginsberg G, et al. Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J Immunol. American Association of Immunologists; 2010;185: 5169–79. doi: 10.4049/jimmunol.1001801 20889546
6. Gillin JS, Shike M, Alcock N, Urmacher C, Krown S, Kurtz RC, et al. Malabsorption and mucosal abnormalities of the small intestine in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;102: 619–22. Available: http://www.ncbi.nlm.nih.gov/pubmed/3985513 3985513
7. Lau K-K, Chan Y-H, Yiu K-H, Tam S, Li S-W, Lau C-P, et al. Incremental predictive value of vascular assessments combined with the Framingham Risk Score for prediction of coronary events in subjects of low-intermediate risk. Postgraduate medical journal. 2008. pp. 153–157. doi: 10.1136/pgmj.2007.064089 18372487
8. Li Q, Estes JD, Duan L, Jessurun J, Pambuccian S, Forster C, et al. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J Infect Dis. 2008;197: 420–9. doi: 10.1086/525046 18199035
9. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 2010;6: e1001052. doi: 10.1371/journal.ppat.1001052 20808901
10. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism. Sci Transl Med. 2013;5: 193ra91. doi: 10.1126/scitranslmed.3006438 23843452
11. Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane A V, et al. The Intestinal Microbiota, Microbial Translocation and Systemic Inflammation in Chronic HIV Infection. J Infect Dis. 2014; doi: 10.1093/infdis/jiu409
12. Vázquez-Castellano JF, Serrano-Villar S, Latorre A, Artacho A, Ferrus ML, Madrid N, et al. Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals. Mucosal Immunol. 2015;8: 760–772. doi: 10.1038/mi.2014.107 25407519
13. Lozupone C, Li M, Campbell TB, Flores SC, Linderman D, Gebert MJ, et al. Alterations in the gut microbiota associated with HIV-1 infection. Cell Host Microbe. Elsevier Inc.; 2013;14: 329–39. doi: 10.1016/j.chom.2013.08.006 24034618
14. Tenorio AR, Chan ES, Bosch RJ, Macatangay BJC, Read SW, Yesmin S, et al. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy—ACTG A5286. J Infect Dis. 2015;211: 780–90. doi: 10.1093/infdis/jiu515 25214516
15. Tenorio AR, Zheng Y, Bosch RJ, Deeks SG, Rodriguez B, Krishnan S, et al. Soluble Markers of Inflammation & Coagulation, but not T-Cell Activation, Predict Non-AIDS- Defining Events During Suppressive Antiretroviral Therapy (ART). Conference of Retrovirus and Opportunistic Infections, Boston, MA. 2014.
16. Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10: e1004543. doi: 10.1371/journal.ppat.1004543 25503054
17. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, et al. Antiretroviral Therapy Initiated within 6 Months of HIV Infection is Associated with Lower T-Cell Activation and Smaller HIV Reservoir Size. J Infect Dis. 2013;208: 1202–11. doi: 10.1093/infdis/jit311 23852127
18. Fletcher C V, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci. 2014;111: 2307–12. doi: 10.1073/pnas.1318249111 24469825
19. Chun T-W, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008;197: 714–20. doi: 10.1086/527324 18260759
20. Asmuth DM, Goodrich J, Cooper DA, Haubrich R, Rajicic N, Hirschel B, et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010;54: 394–7. doi: 10.1097/QAI.0b013e3181c5c83b 20009949
21. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One. 2010;5: e13188. doi: 10.1371/journal.pone.0013188 20949133
22. Gutiérrez C, Díaz L, Vallejo A, Hernández-Novoa B, Abad M, Madrid N, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One. 2011;6: e27864. doi: 10.1371/journal.pone.0027864 22174752
23. Walker DK, Bowers SJ, Mitchell RJ, Potchoiba MJ, Schroeder CM, Small HF, Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica. 2008;38: 1330–9. doi: 10.1080/00498250802447409 18853388
24. Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012;206: 534–42. doi: 10.1093/infdis/jis376 22740718
25. Asmuth DM, Ma Z-M, Mann S, Knight TH, Yotter T, Albanese A, et al. Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. AIDS. 2012;26: 1625–34. doi: 10.1097/QAD.0b013e3283546595 22820612
26. Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, et al. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy. Aids. 2012;26: 167–174. doi: 10.1097/QAD.0b013e32834e8955 22089379
27. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007;21: 2315–21. doi: 10.1097/QAD.0b013e3282f12377 18090280
28. Patterson KB, Prince H a, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS. 2013;27: 1413–9. doi: 10.1097/QAD.0b013e32835f2b49 23945503
29. Critchfield JW, Lemongello D, Walker DH, Garcia JC, Asmuth DM, Pollard RB, et al. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol. 2007;81: 5460–71. doi: 10.1128/JVI.02535-06 17344302
30. Shacklett BL, Critchfield JW, Lemongello D, Isolating mucosal lymphocytes from biopsy tissue for cellular immunology assays. Methods Mol Biol. 2009;485: 347–56. doi: 10.1007/978-1-59745-170-3_23 19020836
31. Sallusto F, Geginat J, Lanzavecchia A, Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22: 745–63. doi: 10.1146/annurev.immunol.22.012703.104702 15032595
32. Asmuth DM, Ma Z-M, Albanese A, Sandler NG, Devaraj S, Knight TH, et al. Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS. 2013;27: 2207–17. doi: 10.1097/QAD.0b013e328362e54c 23660579
33. Li Q, Duan L, Estes JD, Ma Z-M, Rourke T, Wang Y, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature. 2005;434: 1148–52. doi: 10.1038/nature03513 15793562
34. Vaccari M, Boasso A, Ma Z-M, Cecchinato V, Venzon D, Doster MN, et al. CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection. Mucosal Immunol. 2008;1: 497–507. doi: 10.1038/mi.2008.60 19079217
35. Chun T-W, Justement JS, Lempicki RA, Yang J, Dennis G, Hallahan CW, et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A. 2003;100: 1908–13. doi: 10.1073/pnas.0437640100 12552096
36. Brown KC, Patterson KB, Malone S a, Shaheen NJ, Prince HMA, Dumond JB, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011;203: 1484–1490. doi: 10.1093/infdis/jir059 21502084
37. Thompson CG, Bokhart MT, Sykes C, Adamson L, Fedoriw Y, Luciw PA, et al. Mass Spectrometry Imaging Reveals Heterogeneous Efavirenz Distribution within Putative HIV Reservoirs. Antimicrob Agents Chemother. 2015;59: 2944–8. doi: 10.1128/AAC.04952-14 25733502
38. Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF, Engels E a, Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS. 2009;23: 385–93. doi: 10.1097/QAD.0b013e3283213046 19114864
39. Serrano-Villar S, Sainz T, Lee S a, Hunt PW, Sinclair E, Shacklett BL, Silvestri G, et al. HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. PLoS Pathog. Public Library of Science; 2014;10: e1004078. doi: 10.1371/journal.ppat.1004078 24831517
40. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez B a, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009;48: 350–361. doi: 10.1086/595888 19123865
41. Mudd JC, Lederman MM, CD8 T cell persistence in treated HIV infection. Curr Opin HIV AIDS. 2014;9: 500–5. doi: 10.1097/COH.0000000000000086 25010897
42. Deeks SG, HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62: 141–155. doi: 10.1146/annurev-med-042909-093756 21090961
43. Kaech SM, Ahmed R, Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol. 2001;2: 415–22. doi: 10.1038/87720 11323695
44. Cho J-H, Boyman O, Kim H-O, Hahm B, Rubinstein MP, Ramsey C, et al. An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. J Exp Med. 2007;204: 1787–801. doi: 10.1084/jem.20070740 17664294
45. Cho J-H, Kim H-O, Kim K-S, Yang D-H, Surh CD, Sprent J, Unique features of naive CD8+ T cell activation by IL-2. J Immunol. American Association of Immunologists; 2013;191: 5559–73. doi: 10.4049/jimmunol.1302293 24166977
46. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M, Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434: 1093–1097. doi: 10.1542/peds.2006-0900HHHH 15793563
47. Klatt NR, Chomont N, Douek DC, Deeks SG, Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013;254: 326–42. doi: 10.1111/imr.12065 23772629
48. Best BM, Koopmans PP, Letendre SL, Capparelli E V, Rossi SS, Clifford DB, et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011;66: 354–7. doi: 10.1093/jac/dkq434 21098541
49. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49: 4721–32. doi: 10.1128/AAC.49.11.4721–4732.2005 16251317
50. Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother. 2010;54: 5156–60. doi: 10.1128/AAC.00507-10 20876368
51. Cassol E, Malfeld S, Mahasha P, Bond R, Slavik T, Seebregts C, et al. Impaired CD4+ T-cell restoration in the small versus large intestine of HIV-1-positive South Africans receiving combination antiretroviral therapy. J Infect Dis. 2013;208: 1113–22. doi: 10.1093/infdis/jit249 23749968
52. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010;202: 1553–61. doi: 10.1086/656722 20939732
53. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24: 2451–60. doi: 10.1097/QAD.0b013e32833ef7bb 20827162
54. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. Nature Publishing Group; 2010;16: 460–5. doi: 10.1038/nm.2111 20228817
55. Gutiérrez C, Hernández-Novoa B, Vallejo A, Serrano-Villar S, Abad-Fernández M, Madrid N, et al. Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials. AIDS. 2013;27: 2081–2088. doi: 10.1097/QAD.0b013e328361d0e1 24384589
56. Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;59: 229–35. doi: 10.1097/QAI.0b013e31823fd1f2 22083073
57. Lafeuillade A, Assi A, Poggi C, Bresson-Cuquemelle C, Jullian E, Tamalet C, Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial. AIDS Res Ther. 2014;11: 33. doi: 10.1186/1742-6405-11-33 25320633
58. Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez-Alvárez N, et al. Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. J Antimicrob Chemother. 2013;68: 2358–62. doi: 10.1093/jac/dkt183 23677919
59. Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS. 2014;28: 325–34. doi: 10.1097/QAD.0000000000000066 24185044
60. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, Emery S, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. Public Library of Science; 2012;7: e33948. doi: 10.1371/journal.pone.0033948 22479485
61. Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood. 2013;121: 4635–46. doi: 10.1182/blood-2012-06-436345 23589670
62. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee T- H, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011;203: 960–8. doi: 10.1093/infdis/jiq138 21402547
63. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis. 2013;208: 1436–42. doi: 10.1093/infdis/jit453 23975885
64. Guan E, Wang J, Roderiquez G, Norcross MA, Natural truncation of the chemokine MIP-1 beta /CCL4 affects receptor specificity but not anti-HIV-1 activity. J Biol Chem. 2002;277: 32348–52. doi: 10.1074/jbc.M203077200 12070155
65. Madrid N, Hernández-Novoa B, Sastre-Turrión B, Serrano-Villar S, Salomon A, Gutiérrez C, et al. Maraviroc reverts latent HIV-1 in ART suppressed patients through NF-kB without viral load increase. Abstract #P-F8. Conference of Retrovirus and Opportunistic Infections, Boston, MA. 2014.
66. Pérez-Matute P, Pérez-Martinez L, Blanco JR, Oteo JA. Maraviroc, a CCR5 Antagonist, Alters Gut Microbiota Composition in a Mouse Model of Obesity. Conference on Retrovirus and Opportunistic Infections, Boston, MA. 2014.